1-6 of 6
Kyle McFarland
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

Mark A. Schroeder, Michael P. Rettig, Sandra Lopez, Stephanie Christ, Mark Fiala, William Eades, Fazia A. Mir, Jin Shao, Kyle McFarland, Kathryn Trinkaus, William Shannon, Elena Deych, Jinsheng Yu, Ravi Vij, Keith Stockerl-Goldstein, Amanda F. Cashen, Geoffrey L. Uy, Camille N. Abboud, Peter Westervelt, John F. DiPersio
Journal: Blood
Blood (2017) 129 (19): 2680–2692.
https://doi.org/10.1182/blood-2016-09-739722
Published: 2017
Includes: Supplemental data
Journal Articles

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

Clinical Trials & Observations
Geoffrey L. Uy, Michael P. Rettig, Ibraheem H. Motabi, Kyle McFarland, Kathryn M. Trinkaus, Lindsay M. Hladnik, Shashikant Kulkarni, Camille N. Abboud, Amanda F. Cashen, Keith E. Stockerl-Goldstein, Ravi Vij, Peter Westervelt, John F. DiPersio
Journal: Blood
Blood (2012) 119 (17): 3917–3924.
https://doi.org/10.1182/blood-2011-10-383406
Published: 2012
Includes: Supplemental data
Journal Articles

Rapid and Prolonged Mobilization of Human CD34+ Hematopoietic Stem Cells Following Intravenous (IV) Administration of Plerixafor

Michael P. Rettig, PhD, Sandra Lopez, MD, Kyle McFarland, John F. DiPersio, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2261.
https://doi.org/10.1182/blood.V116.21.2261.2261
Published: 2010
Journal Articles

Preferential Mobilization of CD34+ Plasmacytoid Dendritic Cell Precursors by Plerixafor.

Michael P. Rettig, PhD, Kyle McFarland, Julie Ritchey, Matthew Holt, Elena Deych, PhD, Sandra Lopez, Jeremy Gabriel, Stephanie L Bauer, FNP, Amanda F Cashen, MD, John F. DiPersio, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 32.
https://doi.org/10.1182/blood.V114.22.32.32
Published: 2009
Journal Articles

A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.

Geoffrey L. Uy, MD, Michael P. Rettig, PhD, Kyle McFarland, Lindsay Hladnik, PharmD, Shashikant Kulkarni, PhD, Camille N. Abboud, MD, Amanda F Cashen, MD, Keith Stockerl-Goldstein, MD, Ravi Vij, MD, Peter Westervelt, MD, PhD, John F. DiPersio, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 787.
https://doi.org/10.1182/blood.V114.22.787.787
Published: 2009
Journal Articles

Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor

Michael P. Rettig, PhD, William D. Shannon, PhD, Julie Ritchey, Matthew Holt, Kyle McFarland, Sandra Lopez, Jeremy Gabriel, John F. DiPersio, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3476.
https://doi.org/10.1182/blood.V112.11.3476.3476
Published: 2008